

FORM PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 6235-59221
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. § 371		U.S. APPLICATION NO. (If known, see 37 C.F.R. § 1.5) 09/869475
INTERNATIONAL APPLICATION NO. PCT/JP00/07502	INTERNATIONAL FILING DATE 26 October 2000	PRIORITY DATE CLAIMED 29 October 1999
TITLE OF INVENTION GENE THERAPY FOR DIABETIC ISCHEMIC DISEASE		
APPLICANT(S) FOR DO/EO/US Ryuichi Morishita and Toshio Ogihara		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. § 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. § 371. 3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. § 371(f) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. § 371(b) and PCT Articles 22 and 39(1). 4. <input type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. § 371(c)(2)) <ol style="list-style-type: none"> a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input checked="" type="checkbox"/> A translation of the International Application into English (35 U.S.C. § 371(c)(2)) 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. § 371(c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made, however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. § 371(c)(3)). 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. § 371(c)(4)) (UNSIGNED). 10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. § 371(c)(5)). 		
Items 11. to 16. below concern document(s) or information included:		
<ol style="list-style-type: none"> 11. <input type="checkbox"/> An Information Disclosure Statement under 37 C.F.R. §§ 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. §§ 3.28 and 3.31 and the Recordal fee of \$40.00 is included. 13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. 14. <input type="checkbox"/> A substitute specification. 15. <input type="checkbox"/> A change of power of attorney and/or address letter. 16. <input type="checkbox"/> Other items or information: <ul style="list-style-type: none"> <input type="checkbox"/> Written Opinion. <input type="checkbox"/> Preliminary Examination Report. <input type="checkbox"/> International Search Report. <input type="checkbox"/> Copies of References Cited. 		




24197

09869475-101001

WDN:gle 06/28/01 6235-59221 58460.doc

EXPRESS MAIL LABEL NO. EL828141773US
DATE OF DEPOSIT: June 28, 2001

U.S. APPLICATION NO. (If known, see 37 C.F.R. § 1.42) 09/869475		INTERNATIONAL APPLICATION NO. PCT/JP00/07502		ATTORNEY'S DOCKET NUMBER 6235-59221	
17. <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATIONS (PTO USE ONLY)	
BASIC NATIONAL FEE (37 C.F.R. §§ 1.492(a)(1)-(5)): Neither International Preliminary Examination fee (37 C.F.R. § 1.482) nor International Search fee (37 C.F.R. § 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO.....\$1,000.00 International Preliminary Examination fee (37 C.F.R. § 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO.....\$860.00 International Preliminary Examination fee (37 C.F.R. § 1.482) not paid to USPTO but International Search fee (37 C.F.R. § 1.445(a)(2)) paid to USPTO.....\$710.00 International Preliminary Examination fee paid to USPTO (37 C.F.R. § 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4).....\$690.00 International Preliminary Examination fee paid to USPTO (37 C.F.R. § 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4).....\$100.00					
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$	860.00
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. § 1.492(e)).				\$	130.00
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	21 - 20 =	1	x \$18.00	\$	18.00
Independent Claims	3 - 3 =	0	x \$80.00	\$	0.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00	\$	0.00
TOTAL OF ABOVE CALCULATIONS =				\$	1,008.00
<input checked="" type="checkbox"/> Reduction of 1/2 for filing by small entity. Small entity status is claimed for this application.				\$	504.00
SUBTOTAL =				\$	504.00
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 Months from the earliest claimed priority date (37 C.F.R. §§ 1.492(f)).				\$	
TOTAL NATIONAL FEE =				\$	504.00
Fee for recording the enclosed assignment (37 C.F.R. § 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. §§ 3.28, 3.31). \$40.00 per property.				\$	
TOTAL FEES ENCLOSED =				\$	504.00
				REFUND →	\$
				CHARGE →	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$ 504.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Director is hereby authorized to charge any additional fees that may be required, or credit any overpayment, to Deposit Account No. 02-4550. A duplicate copy of this sheet is enclosed. d. <input checked="" type="checkbox"/> Please return the enclosed postcard to confirm that the items listed above have been received.					
NOTE: Where an appropriate time limit under 37 C.F.R. § 1.494 or § 1.495 has not been met, a petition to revive (37 C.F.R. § 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO:					
KLARQUIST SPARKMAN CAMPBELL LEIGH & WHINSTON, LLP One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, OR 97204-2988					
SIGNATURE  William D. Noonan M.D. NAME 30,878 REGISTRATION NUMBER					

cc: Docketing

09/869475

JC03 Rec'd PCT/PTO

28 JUN 2001

WDN/SAS:gte 06/28/01 58735.doc

EXPRESS MAIL LABEL NO. EL828141773US

DATE OF DEPOSIT: June 28, 2001

Attorney Reference Number 6235-59221

Application Number

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Morishita and Ogihara

Art Unit: To Be Assigned

Application No. To Be Assigned

Filed: Herewith

For: GENE THERAPY FOR DIABETIC ISCHEMIC
DISEASE

Examiner: To Be Assigned

Date: June 28, 2001

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on June 28, 2001 as Express Mail Label No. EL828141773US in an envelope addressed to: BOX PCT, COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231.

William D. Noonan, M.D.
Attorney for Applicant

BOX PCT
COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

PRELIMINARY AMENDMENT

Prior to examination of the above-referenced application, please amend the application as follows:

In the specification:

On page 1, line 4, please insert the following paragraph:

--Priority Claim

This application claims priority under 35 U.S.C. § 371 to PCT Application No. PCT/JP00/07502, filed October 26, 2000, which claims priority to Japanese Patent Application No. 11/309984, filed October 29, 1999, each of which is incorporated by reference in its entirety herein.--

In the claims:

1. (Amended) A therapeutic agent for treating a diabetic ischemic disease, comprising a therapeutically effective amount of a nucleic acid encoding hepatocyte growth factor (HGF).

PATENT

2. (Reiterated) The therapeutic agent according to claim 1, used for administration to the ischemic site.

3. (Amended) The therapeutic agent according to claim 1, wherein the diabetic ischemic disease is selected from the group consisting of diabetic lower limb ischemic disease, diabetic ischemic neuropathy and diabetic ischemic myocardial infarction.

4. (Reiterated) The therapeutic agent according to claim 3, wherein the diabetic ischemic disease is diabetic lower limb ischemic disease.

5. (Amended) The therapeutic agent according to claim 1 wherein the administration is into the muscle of the ischemic site.

6. (Amended) The therapeutic agent according to claim 1, wherein the nucleic acid encoding the HGF is in the form of a Sendai virus (HVJ)-liposome.

7. (Amended) The therapeutic agent according to claim 1 wherein the administration is repeated.

8. (Amended) The therapeutic agent according to claim 1 comprising at least 50 μ g of the nucleic acid encoding the HGF.

9. (Amended) A method for the treatment of a diabetic ischemic disease, comprising administering a therapeutically effective amount of a nucleic acid encoding hepatocyte growth factor, thereby treating the diabetic ischemic disease.

10. (Reiterated) The method according to claim 9, wherein the HGF gene is administered to an ischemic site.

PATENT

11. (Amended) The method according to claim 9, wherein the diabetic ischemic disease is selected from the group consisting of diabetic lower limb ischemic disease, diabetic ischemic neuropathy and diabetic ischemic myocardial infarction.

12. (Reiterated) The method according to claim 11, wherein the diabetic ischemic disease is diabetic lower limb ischemic disease.

13. (Amended) The method according to claim 9, wherein the nucleic acid encoding HGF is administered into the muscle of ischemic site.

14. (Amended) The method according to claim 9, wherein the HGF gene is in the form of a Sendai virus (HVJ)-liposome.

15. (Amended) The method according to claim 9, wherein the nucleic acid encoding the HGF is administered repeatedly.

16. (Amended) The method according to claim 9, wherein at least 50 μ g of the nucleic acid encoding the HGF is administered to the subject.

17. (Amended) Use of a nucleic acid encoding HGF for preparing therapeutic agents for diabetic ischemic disease.

18. (Amended) The use according to claim 17, wherein the diabetic ischemic disease is selected from the group consisting of diabetic lower limb ischemic disease, diabetic ischemic neuropathy and diabetic ischemic myocardial infarction.

19. (Reiterated) The use according to claim 18, wherein the diabetic ischemic disease is diabetic lower limb ischemic disease.

PATENT

20. (Amended) The use according to claim 17, wherein the nucleic acid encoding HGF is in the form of a Sendai virus (HVJ)-liposome.

21. (Amended) The use according to claim 17, wherein the amount of the nucleic acid encoding the HGF is at least 50 µg.

REMARKS

Claims 1-21 are amended to correct form. No new matter is added. Entry of this amendment is respectfully requested.

CONCLUSION

If any minor matters remain to be discussed prior to examination, the Examiner is invited to contact the undersigned at the telephone number listed below.

Respectfully submitted,

KLARQUIST SPARKMAN CAMPBELL
LEIGH & WHINSTON, LLP

By _____
William D. Noonan, M.D.
Registration No. 30,878

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

PATENT

**Marked-up Version of Amended Claims and Specification
Pursuant to 37 C.F.R. §§ 1.121(b)-(c)**

CLAIMS

1. (Amended) A therapeutic agent for treating a diabetic ischemic disease, [which comprises] comprising a therapeutically effective amount of a nucleic acid encoding hepatocyte growth factor (HGF) [as the effective ingredient].
2. (Reiterated) The therapeutic agent according to claim 1, used for administration to the ischemic site.
3. (Amended) The therapeutic agent according to claim 1 [or 2], wherein the diabetic ischemic disease is selected from the group consisting of diabetic lower limb ischemic disease, diabetic ischemic neuropathy [or] and diabetic ischemic myocardial infarction.
4. (Reiterated) The therapeutic agent according to claim 3, wherein the diabetic ischemic disease is diabetic lower limb ischemic disease.
5. (Amended) The therapeutic agent according to [any of claims] claim 1 [to 4, used for] wherein the administration is into the muscle of the ischemic site.
6. (Amended) The therapeutic agent according to [any of claims] claim 1 [to 5], wherein the nucleic acid encoding the HGF [gene] is in the form of a Sendai virus (HVJ)-liposome.
7. (Amended) The therapeutic agent according to [any of claims] claim 1 [to 6, which is to be administered repeatedly as needed] wherein the administration is repeated.

PATENT

8. (Amended) The therapeutic agent according to [any of claims] claim 1 [to 7], [wherein the amount of HGF gene used is] comprising at least 50 µg of the nucleic acid encoding the HGF.

9. (Amended) A method for the treatment of a diabetic ischemic disease, [which comprises the transfer of the HGF gene into human] comprising administering a therapeutically effective amount of a nucleic acid encoding hepatocyte growth factor, thereby treating the diabetic ischemic disease.

10. (Reiterated) The method according to claim 9, wherein the HGF gene is administered to an ischemic site.

11. (Amended) The method according to claim 9 [or 10], wherein the diabetic ischemic disease is selected from the group consisting of diabetic lower limb ischemic disease, diabetic ischemic neuropathy [or] and diabetic ischemic myocardial infarction.

12. (Reiterated) The method according to claim 11, wherein the diabetic ischemic disease is diabetic lower limb ischemic disease.

13. (Amended) The method according to [any of claims] claim 9 [to 12], wherein the nucleic acid encoding HGF [gene] is administered into the muscle of ischemic site.

14. (Amended) The method according to [any of claims] claim 9 [to 13], wherein the HGF gene is in the form of a Sendai virus (HVJ)-liposome.

15. (Amended) The method according to [any of claims] claim 9 [to 14], wherein the nucleic acid encoding the HGF [gene] is administered repeatedly [as needed].

PATENT

16. (Amended) The method according to [any of claims] claim 9 [to 15], wherein [the amount of HGF gene to be administered is] at least 50 μ g of the nucleic acid encoding the HGF is administered to the subject.

17. (Amended) Use of [the] a nucleic acid encoding HGF [gene] for preparing therapeutic agents for diabetic ischemic disease.

18. (Amended) The use according to claim 17, wherein the diabetic ischemic disease is selected from the group consisting of diabetic lower limb ischemic disease, diabetic ischemic neuropathy [or] and diabetic ischemic myocardial infarction.

19. (Reiterated) The use according to claim 18, wherein the diabetic ischemic disease is diabetic lower limb ischemic disease.

20. (Amended) The use according to [any of claims] claim 17 [to 19], wherein the nucleic acid encoding HGF [gene] is in the form of a Sendai virus (HVJ)-liposome.

21. (Amended) The use according to [any of claims] claim 17 [to 20], wherein the amount of the nucleic acid encoding the HGF [gene to be used] is at least 50 μ g.

00360475.101001

DESCRIPTION

GENE THERAPY FOR DIABETIC ISCHEMIC DISEASE5 Technical Field

10 The present invention relates to a gene therapy agent and gene therapy method for diabetic ischemic disease utilizing a hepatocyte growth factor (HGF) gene. More specifically, the present invention relates to a method of gene therapy for diabetic ischemic disease which comprises the noninvasive administration of therapeutic agents of diabetic ischemic disease comprising an HGF gene as the effective ingredient or HGF gene.

15 Background Art

15 HGF is a protein that was first discovered as a strong growth factor for mature hepatocytes and the gene encoding it has been cloned (Biochem.Biophys.Res.Commun. 122, 1450 (1984); Proc.Natl.Acad.Sci.USA 83, 6489 (1986); FEBS Letter 22, 231 (1987); Nature 342, 440 (1989); Proc.Natl.Acad.Sci.USA 87, 3200 (1991)).
20 Afterwards, according to researches, it has been revealed that HGF does not only work for repair and regeneration of the damaged liver, as a hepatocyte regeneration factor in vivo, but also has an angiogenic function and plays an important role in treatment and prevention of ischemic disease and artery disease (Symp.Soc.Exp.Biol. 47cell
25 behavior, 227-234 (1993); Proc.Natl.Acad.Sci.USA 90, 1937-1941 (1993); Circulation 97, 381-390 (1998)). That is, it has been reported that upon administration of HGF to the rabbit lower limb ischemic model, significant angiogenesis is observed and improvement in blood flow, repression of blood pressure decrease and improvement in ischemic
30 symptoms take place. According to these reports, it is believed today that HGF expresses and functions as one of the angiogenic factors.

As stated above, HGF has various functions to begin with functions as angiogenic factor, and many attempts have been made to use it as a drug. However, the half life of HGF in blood arose as a problem.
35 The half life of HGF is as short as about 10 minutes, making it difficult to maintain its concentration in blood. Thus, problems arose as to

how to deliver effective levels of HGF to the affected site.

Generally it is common knowledge that protein preparations are mostly administered intravenously and concerning the case above of HGF administration for the ischemic disease model, examples of intravenous and intra-arterial administration are shown (Circulation 97, 381-390 (1998)). In spite of the fact that effectiveness against ischemic disease or artery disease of intravenous or intra-arterial HGF administration to such animal models are revealed, specific administration methods, doses and so on effective for HGF are still under investigation. Particular effective administration methods or doses and such for HGF proteins are still to be determined, due to problems concerning its half life and delivery to the affected site described above.

On the other hand, the rapid progress lately in molecular biology has made it possible to activate cellular function by gene transfer methods and various attempts have been made. Some trials have been made for gene therapy of the heart region. There are some methods, like the coronary diffusional infusion method and such, reported for gene transfer methods but there is no case of gene transfer methods to the ischemic site, particularly intramuscular infusion method to the skeletal muscle showing effects on specific diabetic ischemic disease.

Further, it is known that angiogenesis hardly occurs and prognosis is unfavorable in ischemic disease complicated with or caused by diabetes. At present, it is not known whether HGF gene administration to such diabetic ischemic disease is effective or not.

Disclosure of the Invention

The object of this invention is to provide therapeutic agents and treatment methods for diabetic ischemic disease that utilize the HGF gene.

Inventors investigated to find out whether the HGF gene can be adapted to diabetic ischemic disease and revealed that extremely effective results are obtained by administering HGF gene directly to the ischemic affected site. Specifically, relating to lower limb ischemic disease, it was found out that effective results are obtained

by administering HGF gene to the lower limb layer. As mentioned above, it is known that angiogenesis hardly occurs and prognosis is unfavorable in ischemic disease complicated with or caused by diabetes. Therefore, unlike mere ischemic disease, it had been unknown whether the HGF gene is effective toward diabetic ischemic disease. This invention revealed the effectiveness of the HGF gene for diabetic ischemic disease for the first time.

Since this method is a noninvasive treatment, it has the advantage that it is possible to administer the present gene repeatedly according to the condition.

Thus, the outline of the present invention is as follows:

- (1) a therapeutic agent for diabetic ischemic disease, which comprises hepatocyte growth factor (HGF) as the effective ingredient;
- (2) the therapeutic agent according to (1), used for administration to the ischemic site;
- (3) the therapeutic agent according to (1) or (2), wherein the diabetic ischemic disease is selected from the group consisting of diabetic lower limb ischemic disease, diabetic ischemic neuropathy or diabetic ischemic myocardial infarction;
- (4) the therapeutic agent according to (3), wherein the diabetic ischemic disease is diabetic lower limb ischemic disease;
- (5) the therapeutic agent according to any of (1) to (4), used for administration into the muscle of the ischemic site;
- (6) the therapeutic agent according to any of (1) to (5), wherein the HGF gene is in the form of a Sendai virus (HVJ)-liposome;
- (7) the therapeutic agent according to any of (1) to (6), which is to be administered repeatedly as needed;
- (8) the therapeutic agent according to any of (1) to (7), wherein the amount of HGF gene used is at least 50 μ g;
- (9) a method for the treatment of diabetic ischemic disease, which comprises the transfer of the HGF gene into human;
- (10) the method according to (9), wherein the HGF gene is administered to an ischemic site;
- (11) the method according to (9) or (10), wherein the diabetic ischemic disease is selected from the group consisting of diabetic lower limb ischemic disease, diabetic ischemic neuropathy or diabetic ischemic

myocardial infarction;

(12) the method according to (11), wherein the diabetic ischemic disease is diabetic lower limb ischemic disease;

(13) the method according to any of (9) to (12), wherein the HGF gene is administered into the muscle of ischemic site;

(14) the method according to any of (9) to (13), wherein the HGF gene is in the form of a Sendai virus (HVJ)-liposome;

(15) the method according to any of (9) to (14), wherein the HGF gene is administered repeatedly as needed;

(16) the method according to any of (9) to (15), wherein the amount of HGF gene to be administered is at least 50 μ g;

(17) use of the HGF gene for preparing therapeutic agents for diabetic ischemic disease;

(18) the use according to (17), wherein the diabetic ischemic disease is selected from the group consisting of diabetic lower limb ischemic disease, diabetic ischemic neuropathy or diabetic ischemic myocardial infarction;

(19) the use according to (18), wherein the diabetic ischemic disease is diabetic lower limb ischemic disease;

(20) the use according to any of (17) to (19), wherein the HGF gene is in the form of a Sendai virus (HVJ)-liposome; and

(21) the use according to any of (17) to (20), wherein the amount of HGF gene to be used is at least 50 μ g.

Brief Description of the Drawings

Figure 1 is a graph showing changes in blood perfusion ratio over time of the group of rats with diabetic lower limb ischemia in reference 1 and of the control group, in which lower limb ischemia was induced in normal rats.

Figure 2 is a graph showing the internal HGF concentration in ischemic muscle of the group of rats with diabetic lower limb ischemia in reference 1 and of the control group, in which lower limb ischemia was induced in normal rats.

Figure 3 shows the the blood perfusion ratio of the group of rats with diabetic lower limb ischemia in reference 1, to which HGF gene was administered or not, and of the control group, in which lower

limb ischemia was induced in normal rats.

Figure 4 is a graph showing the result of a comparison of the number of blood vessels of the group of rats with diabetic lower limb ischemia in reference 1, to which HGF gene was administered or not, and of the control group, in which lower limb ischemia was induced in normal rats by ALP (alkalinephosphatase) staining of the skeletal muscle of the lower limb ischemic site.

Figure 5 is a graph showing the MMP-1 concentration in the culture supernatant of the glucose added angioendothelial cell in reference 2, to which HGF was added or not, and of the control group, to which no glucose was added.

Figure 6 is a graph showing the amount of mRNA of transcription factor which is expressed in the angioendothelial cell, of the group of glucose added angioendothelial cell in reference 3, to which HGF was added or not, and of the control group to which no glucose was added.

Best Mode for Carrying out the Invention

As used herein "HGF gene" means a gene that can express HGF (the HGF protein). Specifically, cDNA of HGF described in Nature 342: 440 (1989); Japanese Patent Publication No., 2777678; Biochem.Biophys.Res.Comm. 163: 967 (1989); and Biochem.Biophys.Res.Comm. 172: 321 (1990) and so on integrated into suitable expression vectors (non-viral vector, viral vector) described below are to be mentioned. The base sequence of the cDNA encoding HGF gene of the present invention has been described in the above literature and is also registered with databases such as GenBank. Thus, based on such sequence information, using a suitable DNA portion as a PCR primer, it is possible to clone the cDNA of HGF, for example, by performing a RT-PCR reaction on mRNA derived from the liver or leukocytes. Such cloning can easily be performed by a person skilled in the art according to a basic textbook, such as Molecular Cloning 2nd Ed., Cold Spring Harbor Laboratory Press (1989).

The HGF genes of the present invention are not restricted to the above mentioned genes but also include those genes that express proteins with substantially the same function as HGF. That is, the

05860475.101001

following genes fall under the category of the HGF gene of the present invention: 1) DNA that hybridize to said cDNA under stringent conditions, and 2) DNA encoding proteins having amino acid sequence in which 1 or more (preferably a few) amino acids are substituted, deleted and/or added to the protein encoded by said cDNA and which encodes proteins having the function as HGF. Above DNAs of 1) and 2) can be readily obtained, for example, by site-directed mutagenesis, PCR method, ordinal hybridization method and so on. Such methods can be easily accomplished according to the above basic textbook.

Subsequently, methods of gene transfer, dosage forms, doses and the like for use in gene therapy of the present invention are explained.

The dosage form of a gene therapy agent comprising the above gene as the effective ingredient to be administered to patients are roughly classified into two groups: one is the case in which a nonviral vector is used, and the other is in which a viral vector is used. Methods for preparation and administration thereof are explained in detail in experimental manuals (Supplement of Experimental Medicine, Basic Technology in gene therapy, Yodosha (1996); Supplement of Experimental Medicine, Experimental Methods in Gene Introduction and Expression Analysis, Yodosha (1997); Handbook for Development and Research of Gene Therapy, Japan Society of Gene Therapy ed., NTS (1999)). Specifics are explained below.

A. Usage of a nonviral vector

Using a recombinant expression vector in which the gene of interest has been integrated into a commonly used gene expression vector, may be used to introduce the gene of interest into cells or tissue by the following method etc.

Illustrative methods of gene transfer into cells include the lipofection method, calcium phosphate co-precipitation method, DEAE-dextran method, direct DNA introduction methods using microglass tubes, and the like.

Regarding methods of gene transfer into the tissue, a recombinant expression vector may be incorporated into the cell by subjecting it to any of the method, such as the method of gene transfer with internal type liposome, method of gene introduction with electrostatic type liposome, HVJ-liposome method, improved HVJ-liposome method

086475.101001

(HVJ-AVE liposome method), receptor-mediated gene introduction method, method of introducing DNA molecules together with carriers (metal particles) by a particle gun, method of directly introducing naked-DNA, method of introduction with positively-charged polymers and the like.

Among them, HVJ-liposome is a fusion product prepared by enclosing DNA into liposome made of lipid bilayer, which is fused to inactivated Sendai virus (Hemagglutinating virus of Japan: HVJ). The HVJ-liposome method is characterized by a very high fusing activity with the cell membrane as compared to the conventional liposome method, and is a preferred mode of introduction. For the method of preparing HVJ-liposome, see the literature for details (Separate volume of Experimental Medicine, Basic Technology in gene therapy, Yodosha (1996); experimental Methods in Gene Introduction and Expression Analysis, Yodosha (1997); J.Clin.Invest. 93:1458-1464(1994); Am.J.Physiol. 271:R1212-1220(1996)) and the like, and experimental examples described below for details. In particular, the Z strain (available from ATCC) is preferred as the HVJ strain, but other HVJ strains (for example, ATCC VR-907 and ATCC VR-105) may also be used.

Furthermore, the method of directly introducing naked-DNA is the most simple method among the methods described above, and in this regard a preferred method of introduction.

Expression vectors as used herein may be any expression vectors so long as they permit the *in vivo* expression of the gene of interest. Examples include expression vectors such as pCAGGS (Gene 108:193-200(1991)), pBK-CMV, pCDNA3.1, pZeoSV (Invitrogen, Stratagene) and the like.

B. Usage of a viral vector

Representative methods that use viral vectors include those using viral vectors such as recombinant adenovirus, retrovirus and the like.

More specifically, the gene of interest can be introduced into a DNA virus such as detoxified retrovirus, adenovirus, adeno-associated virus, herpes virus, vaccinia virus, poxvirus, poliovirus, Sindbis virus, Sendai virus, SV40, human immunodeficiency virus (HIV) and the like, which is then infected to the cell to introduce the gene into the cell.

Among the above viral vectors, the efficiency of infection of

00869475.101001

adenovirus is known to be much higher than that of other viral vectors. In this regard, it is preferred to use an adenovirus vector system.

As methods of introducing a gene therapy agent into a patient, there are *in vivo* methods, which permit direct introduction of the gene therapy agent into the body, and *ex vivo* methods, in which certain cells are removed from a human, wherein the gene therapy agent is introduced and which are then returned into the body (Nikkei Science, April 1994 issue pp.20-24; Monthly Yakuji, 36(1):23-48 (1994); Supplement To Experimental Medicine 12(15) (1994); Handbook for Development and Research of Gene Therapy, NTS (1999)). According to the present invention, the *in vivo* method is preferred.

Dosage forms may take various forms according to various administration regimens described above (for example, liquids). When, for example, an injection containing the gene as the effective ingredient is to be used, said injection may be prepared by dissolving the effective ingredients into a standard solvent (a buffer such as PBS, physiological saline, sterile water, etc.). The injection liquid may then be filter-sterilized with filter as needed, and then filled into sterilized containers. Conventional carriers and so on may be added to the injection. Liposomes, such as HVJ-liposome may take the form of suspensions, frozen formulations, centrifugation-concentrated frozen formulations and the like.

It is possible to use known factors having angiogenic functions, additionally or alone besides the HGF gene used in this invention. For example, it is reported that factors such as VEGF and FGF have an angiogenic function and therefore such genes can be used. Further, growth factors such as EGF are reported to repair cell damage in various tissues and thus genes encoding them can be also used.

The diabetic ischemic disease herein includes diseases such as diabetic lower limb ischemic disease, diabetic ischemic neuropathy and diabetic ischemic cardiac infarction and so on, and the therapeutic agent of this invention can be applied to any of these diseases. Moreover, the therapeutic agent of this invention can be applied not only to patients with critical diabetic ischemic disease but also to patients with progressively mild symptoms.

Proper methods and sites for administration adequate for the

disease or symptom to be treated are selected for the gene therapy agent of this invention. As to the administration methods, parenteral administration methods are preferred. As a preferable administration site, the ischemic site can be mentioned. "Ischemic site" herein refers to the site including the affected site of ischemia and surrounding sites thereof.

Specifically, it is possible to administer into the blood vessel or into the muscle of the ischemic site. However, administration into the muscle of the ischemic site is preferred. In other words, administration into the skeletal muscle of the lower limb ischemic site enables stimulation of angiogenesis in the affected site of ischemia and improvement of bloodflow. Thereby, it enables recovery and normalization of the function of the ischemic site. While in cardiopathy, such as cardiac infarction, it is possible to gain similar effect by administering into the cardiac muscle.

Examples of preferred administration methods include, for example, administration by noninvasive catheter, noninvasive injector and so on. Moreover, administration methods which utilize a noninvasive catheter, noninvasive injector and such under the usage of echo can be mentioned. As a method using noninvasive catheter, for example, injecting HGF genes directly into the cardiac muscle from the ventricle inner space in a cardiopathy can be indicated.

Application of the HGF gene of the present invention makes positive treatment for patients with diabetic ischemic disease possible. For example, it enables the recovery of function in patients with critical symptoms to whom no option, other than surgical excision of the affected site, is left.

Dosage of the therapeutic agent of this invention varies depending on the symptoms of the patient but HGF genes about 1 μ g to about 50 mg, preferably about 10 μ g to about 5 mg, more preferably about 50 μ g to about 5 mg per adult patients can be defined.

The therapeutic agent of this invention is suited for administration once every few days or once every few weeks, and administration once per week is preferred. According to the therapeutic treatment of the invention, genes are administered noninvasively and, therefore, desired genes can be administered as

00059475.101001

much as the condition demands.

The present invention will now be specifically explained with reference to the following examples. It should be noted, however, that the present invention is not limited by these examples in any way.

Materials and Methods

Preparation of HVJ-liposome agent

10 mg dried lipid (a 1:4.8:2 mixture of phosphatidyl serine, phosphatidyl choline and cholesterol) and 200 μ l balanced salt solution (137 μ M NaCl, 5.4 μ M KCl, 10 μ M Tris-HCl; pH7.6) containing HGF gene (100 μ g)-HMG1 (high mobility group 1 nuclear protein, 25 μ g) was mixed and, by stirring vigorously with ultrasonication, liposomes were formed. Purified Sendai virus (Z strain) was irradiated with UV (110erg/mm²/sec) for 3 minutes. Liposome suspension was mixed with Sendai virus (HVJ), heated at 4°C for 10 minutes, and then heated at 37°C for 30 minutes. Free HVJ was discarded and thus obtained HVJ liposome agent.

Experimental Animals

Administered group: ischemic rat of diabetic rat (DM-rat)
Control rat: ischemic rat of normal rat

Administration method of HVJ-liposome agent

By surgically excising the femoral artery of one leg of the diabetic rat (6 weeks old; 6 animals per group), to which diabetes was provoked by interperitoneal administration of streptozotocin, ischemic state in the lower limb site was produced.

HVJ-liposome preparation containing HGF gene was injected to the lower limb skeletal muscle.

Details of examination

After administration of the liposome preparation, the bloodflow of the lower limb was measured by laser Doppler imager (LDI) using laser scatter analysis as the index of bypass circulation formation and effects of improvement in bloodflow. The average of colored histogram of ischemic lower limb to that of the normal lower limb was taken as the perfusion ratio.

The density of blood capillary in the lower limb ischemic site

09869475.101001

5

10

16

2

2

6

Experiment 1

2

Ischemic state in the lower limb site was produced by surgical excision of the femoral artery of one leg of the diabetic rats (6

weeks old; 6 animals per group), to which diabetes was provoked by interperitoneal administration of streptozotocin. After surgical excision of the femoral artery, infusion of HVJ-liposome preparation containing HGF gene (50 µg) was injected into the muscle of the lower limb ischemic site.

After 3 weeks, the perfusion ratio of the ischemic site was measured by laser Doppler imager. The perfusion ratio of the ischemic site of the diabetic lower limb ischemic rat, to which HGF gene was administered, showed significant increase compared to that of the control lower limb ischemic rat or that of the diabetic lower limb ischemic rat above with no administration.

Taking perfusion ration of the control lower limb ischemic rat as 100%, that of the HGF gene untreated diabetic lower limb ischemic rat was 67% and that of the HGF administered diabetic lower limb ischemic rat was 129%. The results are shown in Figure 3 (see Figure 1).

Experiment 2

Effect of HGF gene therapy against diabetic lower limb ischemic rat (II)

Diabetic lower ischemic rat and control lower limb ischemic rat treated as above were prepared and subjected to HGF gene therapy. 5 weeks later, the skeletal muscle of the lower limb ischemic site was taken from each animal, subjected to ALP staining and the blood vessel count per unit area was compared. The blood vessel count of HGF gene untreated diabetic lower limb ischemic rat was significantly smaller as that of the control lower limb ischemic rat, and that of the HGF administered diabetic lower limb ischemic rat was significantly increased. The results are shown in Figure 4.

Reference 2

Influence of glucose concentration and HGF addition against MMP-1 production of the angioendothelial cell

The angioendothelial cells (derived from human aorta) were cultured in three types of serum free medium containing glucose at a concentration of 0, 25 mM and 50 mM, respectively. After 24 hours of cultivation, the MMP-1 concentration in the supernatant of the

culture media was measured.

Each sample was compared to that in which 100 ng/ml of HGF was added 30 minutes before glucose addition.

The MMP-1 concentration of the supernatant decreased significantly depending on the glucose concentration, and it was shown that decrease of MMP-1 was inhibited by HGF treatment. The results are shown in Figure 5.

Reference 3

Effect of HGF against angioendothelial cells (Changes of transcription factor ETS-1 related to angiogenesis)

Cultivation of angioendothelial cell was conducted as in reference 2, and expression of mRNA of the transcription factor ETS-1 in the cell was detected. Taking the mRNA of ETS-1 in the control endothelial cell as 100 %, that of the HGF untreated angioendothelial cell decreased in a glucose dependent manner. On the other hand, HGF treated angioendothelial cells expressed the mRNA of ETS-1 at the same or more level compared to that of the control group ($P < 0.01$). The results are shown in Figure 6.

As described above, angioendothelial cells under high glucose concentration show a decrease in MMP-1 expression, which is a matrix cleaving enzyme essential for angiogenesis, and show a decrease in the expression of mRNA of the transcription factor ETS-1, which is expressed and increases during angiogenesis.

Consequently, it was revealed that angiogenesis hardly occurs under high glucose condition. On the other hand, it was shown that by adding HGF to the angioendothelial cell under high glucose condition, MMP-1 expression and mRNA of ETS-1 expression increases significantly. Thus, it was revealed that HGF makes angiogenesis easier.

Industrial Applicability

The therapeutic agent for diabetic ischemic disease containing an HGF gene as the effective ingredient improves poor angiogenesis specific to the affected site of diabetic ischemia with decrease in HGF expression and shows significant angiogenic effect. Therefore,

it enables the improvement of the condition by increasing the bloodflow in the affected site of ischemia. Moreover, the therapeutic agent of this invention can be administered more than once, depending on the symptoms of the patient, thereby stimulating angiogenesis.

- 5 Therefore, according to these effects, the therapeutic agent of this invention makes it possible to treat diabetic lower limb ischemic disease, diabetic ischemic neuropathy and diabetic cardiac infarction.

09869475.101001

CLAIMS

1. A therapeutic agent for diabetic ischemic disease, which comprises hepatocyte growth factor (HGF) as the effective ingredient.
2. The therapeutic agent according to claim 1, used for administration to the ischemic site.
3. The therapeutic agent according to claim 1 or 2, wherein the diabetic ischemic disease is selected from the group consisting of diabetic lower limb ischemic disease, diabetic ischemic neuropathy or diabetic ischemic myocardial infarction.
4. The therapeutic agent according to claim 3, wherein the diabetic ischemic disease is diabetic lower limb ischemic disease.
5. The therapeutic agent according to any of claims 1 to 4, used for administration into the muscle of the ischemic site.
6. The therapeutic agent according to any of claims 1 to 5, wherein the HGF gene is in the form of a Sendai virus (HVJ)-liposome.
7. The therapeutic agent according to any of claims 1 to 6, which is to be administered repeatedly as needed.
8. The therapeutic agent according to any of claims 1 to 7, wherein the amount of HGF gene used is at least 50 μ g.
9. A method for the treatment of diabetic ischemic disease, which comprises the transfer of the HGF gene into human.
10. The method according to claim 9, wherein the HGF gene is administered to an ischemic site.
11. The method according to claim 9 or 10, wherein the diabetic ischemic disease is selected from the group consisting of diabetic lower limb ischemic disease, diabetic ischemic neuropathy or diabetic ischemic myocardial infarction.
12. The method according to claim 11, wherein the diabetic ischemic disease is diabetic lower limb ischemic disease.
13. The method according to any of claims 9 to 12, wherein the HGF gene is administered into the muscle of ischemic site.
14. The method according to any of claims 9 to 13, wherein the HGF gene is in the form of a Sendai virus (HVJ)-liposome.
15. The method according to any of claims 9 to 14, wherein the HGF gene is administered repeatedly as needed.

16. The method according to any of claims 9 to 15, wherein the amount of HGF gene to be administered is at least 50 μ g.

17. Use of the HGF gene for preparing therapeutic agents for diabetic ischemic disease.

5 18. The use according to claim 17, wherein the diabetic ischemic disease is selected from the group consisting of diabetic lower limb ischemic disease, diabetic ischemic neuropathy or diabetic ischemic myocardial infarction.

10 19. The use according to claim 18, wherein the diabetic ischemic disease is diabetic lower limb ischemic disease.

20. The use according to any of claims 17 to 19, wherein the HGF gene is in the form of a Sendai virus (HVJ)-liposome.

15 21. The use according to any of claims 17 to 20, wherein the amount of HGF gene to be used is at least 50 μ g.

09869475.101001

1/3

FIG. 1





FIG. 2



01-1839-175

2/3

FIG. 3





FIG. 4



09/869

3/3
 FIG. 5





FIG. 6



WDName 08/03/01 6235-59221

COMBINED DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled **GENE THERAPY FOR DIABETIC ISCHEMIC DISEASE**, the specification of which

- ☐ is attached hereto.
- ☐ was filed on _____ as United States Application No. _____.
- ☒ was filed on October 26 2000 as International Application No. PCT/JP00/07502.
- ☐ and was amended on _____ (if applicable).
- ☐ with amendments through _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56. If this is a continuation-in-part application filed under the conditions specified in 35 U.S.C. § 120 which discloses and claims subject matter in addition to that disclosed in the prior copending application, I further acknowledge the duty to disclose material information as defined in 37 C.F.R. § 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(4) of any foreign application(s) for patent or inventor's certificate or of any PCT International application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT International application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) on which priority is claimed:

Prior Foreign Application(s)			Priority Claimed	
<u>11/309984</u> (Number)	<u>Japan</u> (Country)	<u>October 29 1999</u> (Day/Month/Year Filed)	<input checked="" type="checkbox"/> Yes	<input type="checkbox"/> No
<u>PCT/JP00/07502</u> (Number)	<u>PCT</u> (Country)	<u>October 26 2000</u> (Day/Month/Year Filed)	<input checked="" type="checkbox"/> Yes	<input type="checkbox"/> No

WDName 08/09/01 6235-59221

I hereby claim the benefit under Title 35, United States Code, § 119(c) of any United States provisional application(s) listed below:

Application Number

Filing Date

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) or § 365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT International filing date of this application:

(Application No.)

(Filing Date)

(Status: patented,
Pending, abandoned)

The undersigned hereby authorizes the U.S. attorney or agent named herein to accept and follow instructions from Shimizu Patent Office as to any action to be taken in the Patent and Trademark Office regarding this application without direct communication between the U.S. attorney or agent and the undersigned. In the event of a change in the persons from whom instructions may be taken, the U.S. attorney or agent named herein will be so notified by the undersigned.

I hereby appoint the practitioners associated with the customer number provided below to prosecute this application, to file a corresponding international application, and to transact all business in the Patent and Trademark Office connected therewith:

Customer Number



24197

KSC/LW

Name	Reg. No.	Name	Reg. No.
8 BLYVEIS, Deborah B.	47,337	PETERSEN, David P.	28,106
CALDWELL, Lisa M.	41,653	FOLLEY, Richard J.	28,107
GIRARD, Michael P.	38,467	RINEHART, Kyle B.	47,027
HAENDLER, Jeffrey B.	43,652	RUPERT, Wayne W.	34,420
HARDING, Tanya M.	42,630	RYBAK, Sheree L.	47,913
JAKUBEK, Joseph T.	34,190	SCOTTI, Robert F.	39,830
JONCUS, Stephen J.	44,809	SIEGEL, Susan Alpert	43,121
JONES, Michael D.	41,879	SLATER, Stacey C.	36,011
KLARQUIST, Kenneth S.	16,445	STEPHENS Jr., Donald L.	34,022
KLITZKE II, Ramon A.	30,188	STUART, John W.	24,540
LEIGH, James S.	20,434	VANDENBERG, John D.	31,312
MAURER, Gregory L.	43,781	WHINSTON, Arthur L.	19,155
NOONAN, William D.	30,878	WIGHT, Stephen A.	37,759
ORR, David E.	44,988	WINN, Garth A.	33,220

Address all telephone calls to William D. Noonan M.D. at telephone number (503) 226-7391.

Address all correspondence to:

Customer Number



24197

KSC/LW

WDName 08/03/01 6235-59221

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of First Inventor:

Ryuchi Morishita

Inventor's Signature

*Ryuchi Morishita*2001/08/10

Date

Residence:

Osaka, JAPAN JAX

Citizenship:

JAPAN

Post Office Address:

2-11-22-502, Miyahara, Yodogawa-ku, Osaka-shi, Osaka 532-0003, JAPAN

Full Name of Second Inventor:

Toshio Ogihara

Inventor's Signature

*T. Ogihara*2001/08/13

Date

Residence:

Osaka, JAPAN JAX

Citizenship:

JAPAN

Post Office Address:

2-7-29, Sakuragaoka, Minoo-shi, Osaka 562-0046, JAPAN

09669475.101001